Wells Fargo & Company MN Has $670,000 Holdings in Kyverna Therapeutics, Inc. (NASDAQ:KYTX)

Wells Fargo & Company MN lifted its position in Kyverna Therapeutics, Inc. (NASDAQ:KYTX) by 16.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 179,012 shares of the company’s stock after purchasing an additional 25,225 shares during the quarter. Wells Fargo & Company MN owned 0.41% of Kyverna Therapeutics worth $670,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Geode Capital Management LLC raised its stake in shares of Kyverna Therapeutics by 21.7% in the 4th quarter. Geode Capital Management LLC now owns 539,682 shares of the company’s stock valued at $2,019,000 after buying an additional 96,370 shares in the last quarter. Wellington Management Group LLP increased its stake in Kyverna Therapeutics by 16.7% in the fourth quarter. Wellington Management Group LLP now owns 274,414 shares of the company’s stock valued at $1,026,000 after acquiring an additional 39,291 shares during the period. Norges Bank acquired a new position in Kyverna Therapeutics in the fourth quarter worth about $150,000. Corebridge Financial Inc. lifted its stake in Kyverna Therapeutics by 42.3% during the fourth quarter. Corebridge Financial Inc. now owns 12,811 shares of the company’s stock worth $48,000 after purchasing an additional 3,810 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its holdings in Kyverna Therapeutics by 1.9% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 169,780 shares of the company’s stock valued at $635,000 after purchasing an additional 3,145 shares in the last quarter. 18.08% of the stock is owned by institutional investors.

Kyverna Therapeutics Trading Down 3.9 %

NASDAQ:KYTX opened at $2.22 on Friday. The stock has a market capitalization of $95.95 million, a P/E ratio of -0.64 and a beta of 2.57. Kyverna Therapeutics, Inc. has a 1 year low of $1.78 and a 1 year high of $17.55. The firm has a 50 day moving average of $2.26 and a 200-day moving average of $3.52.

Kyverna Therapeutics (NASDAQ:KYTX) last issued its quarterly earnings data on Thursday, March 27th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.87) by ($0.01). As a group, analysts forecast that Kyverna Therapeutics, Inc. will post -3.29 EPS for the current fiscal year.

Analyst Ratings Changes

KYTX has been the subject of a number of recent research reports. Morgan Stanley dropped their target price on Kyverna Therapeutics from $40.00 to $20.00 and set an “overweight” rating for the company in a report on Tuesday, April 1st. HC Wainwright lowered their price target on Kyverna Therapeutics from $6.00 to $4.00 and set a “neutral” rating on the stock in a research report on Thursday, April 3rd. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Kyverna Therapeutics presently has an average rating of “Buy” and a consensus target price of $18.33.

Kyverna Therapeutics Profile

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.